Real-World Characteristics and Treatment Patterns With Nintedanib in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective US Claims Study
Author(s)
Tanzira Zaman, M.D.1, Saloni Shah, MBA2, Geetanjan Singh Ahluwalia, PGPM3, Gary Palmer, MBBCh, MBA4, Greg Cosgrove, M.D., FCCP4, Nazim Haider, B.E, MBA4, Tejaswini Kulkarni, M.D.,MPH,FCCP5;
1Cedars-Sinai Medical Center, Director of Interstitial Lung Diseases Program, Los Angeles, CA, USA, 2Trinity Life Sciences, Waltham, MA, USA, 3Trinity Life Sciences, Gurugram, Haryana, India, 4Pliant Therapeutics, South San Francisco, CA, USA, 5The University of Alabama at Birmingham, Division of Pulmonary, Allergy and Critical Care Medicine, Birmingham, AL, USA
1Cedars-Sinai Medical Center, Director of Interstitial Lung Diseases Program, Los Angeles, CA, USA, 2Trinity Life Sciences, Waltham, MA, USA, 3Trinity Life Sciences, Gurugram, Haryana, India, 4Pliant Therapeutics, South San Francisco, CA, USA, 5The University of Alabama at Birmingham, Division of Pulmonary, Allergy and Critical Care Medicine, Birmingham, AL, USA
Presentation Documents
OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a rare and life-threatening condition leading to a progressive decline in lung function. This study aimed to describe the characteristics of four treatment sub-cohorts of the IPF population.
METHODS: A retrospective, descriptive claims analysis was conducted using Komodo Healthcare Map™ cost of care data between 1st January 2019-31st December 2023. Patients were included in the study at the start of specific dosage of nintedanib or IPF diagnosis in the study period with 12-months of continuous enrollment pre-/post-index date. Descriptive analyses were conducted in the post index period across four comparator cohorts: nintedanib 100mg BID, nintedanib 150mg BID, nintedanib discontinued for 12-months, and untreated with any IPF Therapy.
RESULTS: We identified 10,877 patients with IPF meeting study criteria: 10% were treated with nintedanib 150mg, 5% were treated with nintedanib 100mg, 8% discontinued nintedanib (either dose) for 12 months and a vast majority (79%) were untreated with any IPF therapy. Overall mean age ranged between 68-72 years, with those on nintedanib 150mg being younger (mean=68 years) compared to the other three cohorts. Patients receiving nintedanib 150mg skewed male (72%) compared to the other cohorts (52-58%). Comorbidity rates were high across cohorts with a high prevalence of cardiovascular conditions (~70%-80%) and GERD (49%-58%). Untreated and discontinued patients had higher Charlson Comorbidity Index (CCI) scores (~2.8), compared to treated patients (~2.15). Patients were comparable in other characteristics, such as region and payer mix across cohorts, except nintedanib 150mg patients who had a higher rate of Commercial insurance (36%) compared to other cohorts (20%-23%).
CONCLUSIONS: Despite known morbidity and mortality of IPF and availability of therapy for nearly a decade, there remains a very large untreated population. Understanding patient characteristics across treatment groups in a real-world setting can potentially impact treatment decisions in patients with IPF.
METHODS: A retrospective, descriptive claims analysis was conducted using Komodo Healthcare Map™ cost of care data between 1st January 2019-31st December 2023. Patients were included in the study at the start of specific dosage of nintedanib or IPF diagnosis in the study period with 12-months of continuous enrollment pre-/post-index date. Descriptive analyses were conducted in the post index period across four comparator cohorts: nintedanib 100mg BID, nintedanib 150mg BID, nintedanib discontinued for 12-months, and untreated with any IPF Therapy.
RESULTS: We identified 10,877 patients with IPF meeting study criteria: 10% were treated with nintedanib 150mg, 5% were treated with nintedanib 100mg, 8% discontinued nintedanib (either dose) for 12 months and a vast majority (79%) were untreated with any IPF therapy. Overall mean age ranged between 68-72 years, with those on nintedanib 150mg being younger (mean=68 years) compared to the other three cohorts. Patients receiving nintedanib 150mg skewed male (72%) compared to the other cohorts (52-58%). Comorbidity rates were high across cohorts with a high prevalence of cardiovascular conditions (~70%-80%) and GERD (49%-58%). Untreated and discontinued patients had higher Charlson Comorbidity Index (CCI) scores (~2.8), compared to treated patients (~2.15). Patients were comparable in other characteristics, such as region and payer mix across cohorts, except nintedanib 150mg patients who had a higher rate of Commercial insurance (36%) compared to other cohorts (20%-23%).
CONCLUSIONS: Despite known morbidity and mortality of IPF and availability of therapy for nearly a decade, there remains a very large untreated population. Understanding patient characteristics across treatment groups in a real-world setting can potentially impact treatment decisions in patients with IPF.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD114
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)